Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Next Previous
Trial Profile

A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Revefenacin (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Mylan

Most Recent Events

  • 12 Nov 2024 According to a Theravance media release, the company published YUPELRI FEV1 AUC analysis of registrational Phase 3 Studies 0126 and 0127, in October 2024.
  • 18 Jan 2023 Results of post hoc analysis evaluating improvement in patient reported outcomes (PROs), including the St. Georges Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT), and Clinical COPD Questionnaire (CCQ) in both women and men published in the Respiratory Medicine
  • 19 Oct 2022 Results post hoc analysis (n=812 of two phase 3 trials NCT02459080; NCT02512510) assessing Patient-Reported Outcomes with Revefenacin in Adults with Moderate to Very Severe Copd and Comorbid Anxiety or Depressionpresented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top